Chinook (KDNY) Trial Results Manipulation Case

• In May 2023, Muddy Waters accused Chinook and AbbVie of manipulating trial results for lead product candidate, Atrasentan.

• On it, $KDNY fell 7%, losing $100M+ shareholder value.

• Investors may have reasons to suspect Chinook of unlawful biz practices, which consequently led to their losses.

On May 16, 2023, Muddy Waters Research in its report alleged that Chinook’s (KDNY) lead product candidate, Atrasentan, “is harmful to patients’ cardiovascular health,” and that “AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.”

On this news, $KDNY fell 7% and lost over $100 million of its market capitalization, damaging shareholders.

Considering the information, investors might have grounds to suspect that Chinook and accountables manipulated trial results figures, which consequently led to their losses.

The case is already under investigation by at least one of the reputable law firms.